|Articles|October 1, 2003

Biopharmaceutical Agents for Treating Rheumatoid Arthritis: Impact on Patients and Managed Care Heal
Volume 9
Issue 6 Suppl

Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Author(s)Carolyn R. Harley, PhD, Jennifer R. Frytak, PhD, Neeta Tandon, MA

Download PDF: Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Articles in this issue

over 22 years ago

Article

Participating Faculty

over 22 years ago

Article

Defining and Characterizing the Late-stage Biopharmaceutical Pipeline

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC